{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:21:00Z","timestamp":1776687660869,"version":"3.51.2"},"reference-count":15,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Wockhardt Bio AG Switzerland"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>\n            Levonadifloxacin (WCK 771) was evaluated against 68 type strains and clinical isolates of\n            <jats:named-content content-type=\"genus-species\">Mycoplasma genitalium<\/jats:named-content>\n            ,\n            <jats:named-content content-type=\"genus-species\">Mycoplasma hominis<\/jats:named-content>\n            ,\n            <jats:named-content content-type=\"genus-species\">Mycoplasma pneumoniae<\/jats:named-content>\n            , and\n            <jats:named-content content-type=\"genus-species\">Ureaplasma<\/jats:named-content>\n            spp. in comparison with moxifloxacin, levofloxacin, tetracycline, and azithromycin or clindamycin.\n          <\/jats:p>","DOI":"10.1128\/aac.01348-18","type":"journal-article","created":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T07:09:22Z","timestamp":1534144162000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["<i>In Vitro<\/i>\n            Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms"],"prefix":"10.1128","volume":"62","author":[{"given":"G.","family":"Xue","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA"},{"name":"Department of Bacteriology, Capital Institute of Pediatrics, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M.","family":"Crabb","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"China Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. B.","family":"Waites","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01150-08"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00114-16"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/9781555817381.ch62"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00006-11"},{"key":"e_1_3_2_6_2","first-page":"289","volume-title":"Mollicutes molecular biology and pathogenesis","author":"Waites KB","year":"2014","unstructured":"Waites KB, Lysynyansky I, Bebear CM. 2014. Antibiotic susceptibility testing and resistance in mycoplasmas of humans and animals, p 289\u2013322. In Browning G, Citti C (ed), Mollicutes molecular biology and pathogenesis. Caister Academic Press, Norfolk, United Kingdom."},{"key":"e_1_3_2_7_2","volume-title":"CLSI document M43-A","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. 2011. Methods for antimicrobial susceptibility testing of human mycoplasmas; approved guideline. CLSI document M43-A. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02008-16"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4754-4761.2004"},{"key":"e_1_3_2_10_2","volume-title":"Abstr 26th Eur Congr Clin Microbiol Infect Dis (ECCMID), Amsterdam, Netherlands","author":"Chug R","year":"2016","unstructured":"Chug R, Lakdavala A, Bhatia A. 2016. Safety and pharmacokinetics of multiple ascending doses of WCK 771 and WCK2349, abstr P1268. Abstr 26th Eur Congr Clin Microbiol Infect Dis (ECCMID), Amsterdam, Netherlands. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02297-17"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.3.965"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.4.1114"},{"key":"e_1_3_2_14_2","unstructured":"Bayer Australia Ltd. 2014. Avelox moxifloxacin hydrochloride product information. Bayer Australia Ltd. Pymble New South Wales Australia. http:\/\/www.bayerresources.com.au\/resources\/uploads\/PI\/file9310.pdf."},{"key":"e_1_3_2_15_2","volume-title":"Cipro, ciprofloxacin hydrochloride, product information","author":"Bayer HealthCare Pharmaceuticals Inc","year":"2008","unstructured":"Bayer HealthCare Pharmaceuticals Inc. 2008. Cipro, ciprofloxacin hydrochloride, product information. Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ."},{"key":"e_1_3_2_16_2","volume-title":"Levaquin, levofloxacin, product monograph","author":"Janssen Inc","year":"2014","unstructured":"Janssen Inc. 2014. Levaquin, levofloxacin, product monograph. Janssen Inc., Toronto, Ontario, Canada."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01348-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01348-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:18:28Z","timestamp":1645478308000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01348-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1128\/AAC.01348-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.01348-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"2018-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01348-18"}}